Physicochemical Properties
| Molecular Formula | C17H18N6O2 |
| Molecular Weight | 338.363822460175 |
| Exact Mass | 338.149 |
| CAS # | 1436004-46-4 |
| PubChem CID | 71709695 |
| Appearance | White to light yellow solid powder |
| LogP | 0.4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 25 |
| Complexity | 515 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C1CC(C(NCCC2=CN=CN2)=O)CN1C1C2C=CC=CC=2NN=1 |
| InChi Key | WWPHFXOMYQJGGF-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C17H18N6O2/c24-15-7-11(17(25)19-6-5-12-8-18-10-20-12)9-23(15)16-13-3-1-2-4-14(13)21-22-16/h1-4,8,10-11H,5-7,9H2,(H,18,20)(H,19,25)(H,21,22) |
| Chemical Name | N-[2-(1H-imidazol-5-yl)ethyl]-1-(1H-indazol-3-yl)-5-oxopyrrolidine-3-carboxamide |
| Synonyms | PA9; PA 9; PA-9 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In CHO cells expressing the PAC1 receptor, PA-9 (10 pM to 10 nM; 30 minutes) dose-dependently suppresses PACAP-induced (1 nM) CREB phosphorylation [1]. |
| ln Vivo | When co-injected with PACAP, PA-9 (100 pmol) reduces the development of intrathecal PACAP-induced (100 pmol/5 μL) unpleasant reactions in mice [1]. When co-injected with PACAP, PA-9 (100 pmol) effectively prevents the induction of mechanical allodynia (100 pmol) caused by PACAP [1]. In mice, intrathecal injection of PA-9 (100 pmol/5 μl) does not cause mechanical allodynia or elicit unpleasant reactions [1]. The PAC1 receptor's subpocket, which is made up of L80, F81, I83, G91, V92, P107, A112, and C113, is a good fit for PA-9, which precipitates there through hydrophobic interactions [1]. |
| Animal Protocol |
Animal/Disease Models: Male ddY mice (6 weeks old at the beginning of the experiment; intrathecal injection of 100 pmol/5 μL PACAP) [1] Doses: intrathecal injection, coinjected with PACAP. Route of Administration: 100 pmol/5 μL Experimental Results: Attenuation of the development of PACAP-induced aversive responses. Blocking PACAP-induced mechanical allodynia. |
| References |
[1]. In Silico Screening Identified Novel Small-molecule Antagonists of PAC1 Receptor. J Pharmacol Exp Ther. 2018 Apr;365(1):1-8. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~738.86 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9554 mL | 14.7772 mL | 29.5543 mL | |
| 5 mM | 0.5911 mL | 2.9554 mL | 5.9109 mL | |
| 10 mM | 0.2955 mL | 1.4777 mL | 2.9554 mL |